Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cepheid
Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
April 19th, 2008
Cepheid (NASDAQ:CPHD) announced it has been selected as vendor of choice by the Connecticut Hospital Association (CHA) Shared Services Program for molecular surveillance testing of Methicillin-resistant Staphylococcus aureus (MRSA) with Cepheid's GeneXpert(R) Systems and Xpert(TM) MRSA test. Under the terms of the agreement, which includes a minimum purchase commitment, CHA Shared Services Program will exclusively market Cepheid's GeneXpert Systems and Xpert MRSA test kits to up to 164 of its acute care member hospitals at pre-negotiated prices. The CHA Shared Services Program membership reaches across nine states, including Connecticut, Massachusetts, Maine, Rhode Island, New Hampshire,...
Source: Law & Health Weekly (2008-04-19)
|
